Increased Sodium Concentration in Substantia Nigra in Early Parkinson's Disease: A Preliminary Study With Ultra-High Field (7T) MRI.
Parkinson's disease
biomarker
neurodegeneration
sodium
ultra high field magnetic resonance imaging
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
05
2021
accepted:
17
08
2021
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
28
9
2021
Statut:
epublish
Résumé
Pathophysiology of idiopathic Parkinson's disease (iPD) is complex and still misunderstood. At a time when treatments with disease-modifying potential are being developed, identification of early markers of neurodegeneration is essential. Intracerebral sodium accumulation could be one of them. Indeed, it may be in relation to the mitochondrial dysfunction that early exists in iPD. For the first time, we used brain sodium (
Identifiants
pubmed: 34566858
doi: 10.3389/fneur.2021.715618
pmc: PMC8458803
doi:
Types de publication
Journal Article
Langues
eng
Pagination
715618Informations de copyright
Copyright © 2021 Grimaldi, El Mendili, Zaaraoui, Ranjeva, Azulay, Eusebio and Guye.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Neuropharmacol. 2016 Jan-Feb;39(1):57-9
pubmed: 26757306
Neurology. 2013 Jul 23;81(4):346-52
pubmed: 23794682
Nat Rev Neurosci. 2006 Mar;7(3):207-19
pubmed: 16495942
Neuroreport. 1994 Jul 21;5(12):1533-7
pubmed: 7948856
Nat Commun. 2018 Apr 12;9(1):1422
pubmed: 29651049
Mov Disord. 2008 May 15;23(7):1043-1046
pubmed: 18381646
Sci Rep. 2018 Mar 12;8(1):4357
pubmed: 29531255
Nat Commun. 2016 Nov 22;7:13548
pubmed: 27874000
Mov Disord. 2018 Sep;33(9):1449-1455
pubmed: 30145805
Nat Cell Biol. 2003 Dec;5(12):1041-3
pubmed: 14647298
Sci Rep. 2017 Jul 12;7(1):5248
pubmed: 28701749
Radiology. 2019 Aug;292(2):422-428
pubmed: 31184559
Neurosci Lett. 2018 Jan 10;663:86-90
pubmed: 28838811
Biochem Biophys Res Commun. 2017 Feb 19;483(4):1013-1019
pubmed: 27590583
Nat Rev Neurosci. 2003 Jan;4(1):13-25
pubmed: 12511858
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Neuroimage. 2010 Dec;53(4):1244-55
pubmed: 20600995
Front Neuroinform. 2014 Apr 28;8:44
pubmed: 24817849
Glia. 2016 Oct;64(10):1677-97
pubmed: 27458821
Neuroscience. 1983 Oct;10(2):317-31
pubmed: 6633864
J Neurosci. 2009 Jul 1;29(26):8452-61
pubmed: 19571136
Mov Disord. 2007 Dec;22(16):2386-93
pubmed: 17894337
Mov Disord. 2011 May;26(6):1049-55
pubmed: 21626550
Neuroimage. 2011 Jun 1;56(3):907-22
pubmed: 21352927
J Biol Chem. 2014 Sep 12;289(37):25764-73
pubmed: 25063810
Nat Rev Neurosci. 2006 Dec;7(12):932-41
pubmed: 17115075
Neuroimage. 2012 Oct 15;63(1):517-24
pubmed: 22796981
Prog Neurobiol. 2009 Jun;88(2):89-103
pubmed: 19482226
Mov Disord Clin Pract. 2020 Mar 16;7(3):343-345
pubmed: 32258239
Neuron. 2003 Sep 11;39(6):889-909
pubmed: 12971891
Neuroimage. 2005 Jul 1;26(3):839-51
pubmed: 15955494